Back A A A Font Size Receive E-mail Alerts Press Releases

The First Case of Firehawk® in Kazakhstan Completed


Astana, Kazakhstan – The first case of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in Kazakhstan was successfully completed in National Scientific Medical Center in Astana, Kazakhstan. Firehawk® is a drug-eluting stent in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®").
The surgery was performed by Professor Stambol Beglan of Interventional Cardiology and Endovascular X-ray Surgery Department of National Scientific Medical Center in Astana, Kazakhstan. The patient is an 80-year-old female with calcified CTO at mid-LAD. Professor Stambol Beglan implanted two Firehawk® stents (3.0x38mm, 3.5x38mm) in the LAD lesion, and the two stents were precisely implanted to the LAD and successfully crossed the lesion with full dilation and good apposition. Professor Stambol Beglan was satisfied with the surgical outcome and spoke highly of Firehawk®’s excellent crossability and pushability.
In 2013, the concept of a "Silk Road Economic Belt" was put forward by President Xi Jinping during his visit to Kazakhstan, which together with the "21st Century Maritime Silk Road" forms the "Belt and Road" initiative. The "Belt and Road" initiative integrates not only trade and investment but healthcare and medical treatment as well in Eurasia. In recent years, under the guidance of the "Belt and Road" initiative, MicroPort® is expanding its international business in countries involved in the initiative. Currently, the products of MicroPort® have entered more than 10 "Belt and Road" countries such as India, Pakistan, Indonesia, the Philippines, Thailand, Kazakhstan, Malaysia, Poland, Romania, South Korea, and Turkey.
Dr. Linda Lin, First Vice President of MicroPort® International Business, said: "The outcome of the first Firehawk® case in Kazakhstan won high recognition from local physicians and patients, which paves the way for MicroPort® to further promote its products in Kazakhstan and even the whole Middle Asia. We will continue to introduce more high-quality medical devices to Kazakhstan and other countries involved in the "Belt and Road" initiative, to offer better service to patients."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:First Case of Firehawk® in Tibet Completed
[Next]:MSC CompassAnalyzer™ PSA Completes Patient Enrollment